{"id":"NCT01223027","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma","officialTitle":"An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2010-10-18","resultsPosted":"2015-11-06","lastUpdate":"2015-12-07"},"enrollment":564,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Dovitinib","otherNames":["TKI258"]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"Dovitinib + best supportive care (BSC)","type":"EXPERIMENTAL"},{"label":"Sorafenib + BSC","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.","primaryOutcome":{"measure":"Progression Free Survival (PFS) Per Independent Central Radiology Review","timeFrame":"Until disease progression or discontinuation of treatment due to unacceptable toxicity up to 30-Jun-2014 (discontinuation)","effectByArm":[{"arm":"Dovitinib + Best Supportive Care (BSC)","deltaMin":3.7,"sd":null},{"arm":"Sorafenib + BSC","deltaMin":3.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":199,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Norway","Poland","Saudi Arabia","Slovakia","South Korea","Spain","Sweden","Switzerland","Thailand","United Kingdom"]},"refs":{"pmids":["24556040"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":133,"n":280},"commonTop":["DIARRHOEA","NAUSEA","FATIGUE","DECREASED APPETITE","VOMITING"]}}